HC Wainwright Issues Positive Forecast for NovoCure (NASDAQ:NVCR) Stock Price

NovoCure (NASDAQ:NVCR) had its price target hoisted by HC Wainwright from $47.00 to $49.00 in a research note released on Thursday,Benzinga reports. The brokerage currently has a buy rating on the medical equipment provider’s stock.

A number of other equities research analysts have also recently commented on NVCR. Wedbush reaffirmed a “neutral” rating and set a $18.00 price objective on shares of NovoCure in a research note on Thursday, January 15th. Evercore set a $20.00 price target on shares of NovoCure in a research report on Monday, January 5th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of NovoCure in a report on Thursday, January 22nd. Three analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $26.93.

NovoCure Stock Performance

NASDAQ NVCR opened at $13.75 on Thursday. The firm has a market capitalization of $1.54 billion, a P/E ratio of -8.54 and a beta of 0.73. The stock has a 50-day simple moving average of $12.71 and a two-hundred day simple moving average of $12.63. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.50 and a current ratio of 1.55. NovoCure has a fifty-two week low of $9.82 and a fifty-two week high of $21.55.

NovoCure (NASDAQ:NVCR) last posted its earnings results on Thursday, February 26th. The medical equipment provider reported ($0.22) EPS for the quarter, topping the consensus estimate of ($0.41) by $0.19. The firm had revenue of $174.35 million for the quarter, compared to analyst estimates of $174.40 million. NovoCure had a negative return on equity of 50.29% and a negative net margin of 27.66%.NovoCure’s revenue for the quarter was up 8.2% compared to the same quarter last year. During the same period last year, the company earned ($0.61) earnings per share. On average, equities analysts forecast that NovoCure will post -1.3 earnings per share for the current year.

Institutional Investors Weigh In On NovoCure

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Arizona State Retirement System raised its position in NovoCure by 3.0% during the third quarter. Arizona State Retirement System now owns 31,313 shares of the medical equipment provider’s stock worth $405,000 after acquiring an additional 916 shares during the period. Larson Financial Group LLC increased its stake in shares of NovoCure by 25.2% during the fourth quarter. Larson Financial Group LLC now owns 5,133 shares of the medical equipment provider’s stock worth $66,000 after purchasing an additional 1,033 shares in the last quarter. Alliancebernstein L.P. increased its stake in shares of NovoCure by 0.8% during the third quarter. Alliancebernstein L.P. now owns 137,106 shares of the medical equipment provider’s stock worth $1,771,000 after purchasing an additional 1,076 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its position in shares of NovoCure by 25.9% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,442 shares of the medical equipment provider’s stock worth $70,000 after purchasing an additional 1,120 shares during the last quarter. Finally, Royal Bank of Canada lifted its stake in NovoCure by 14.9% in the 4th quarter. Royal Bank of Canada now owns 12,830 shares of the medical equipment provider’s stock valued at $166,000 after buying an additional 1,667 shares in the last quarter. Hedge funds and other institutional investors own 84.61% of the company’s stock.

Key NovoCure News

Here are the key news stories impacting NovoCure this week:

• Positive Sentiment: Medicare billing for NovoCure was restored, removing a key reimbursement overhang that had pressured near‑term revenue recognition and cash collection; this supports visibility into U.S. revenue and was cited by the market as a major positive catalyst. Novocure stock jumps after Medicare billing restored
• Positive Sentiment: Q4 results beat on EPS (loss of $0.22 vs. consensus -$0.41) and revenue was essentially in line at ~$174.4M (+8% YoY). The smaller-than-expected loss and steady top‑line growth reduce near‑term downside risk versus prior quarters. NovoCure (NVCR) Reports Q4 Loss, Beats Revenue Estimates
• Positive Sentiment: Management set FY‑2026 revenue guidance of $675M–$705M, modestly above street revenue consensus (~$670M), which signals expected continued growth and gives investors a clearer revenue trajectory for the year. Novocure Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Company Update
• Positive Sentiment: HC Wainwright raised its price target to $49 and reiterated a Buy rating, a high-profile analyst endorsement that could attract buyers given the large upside from current levels. Benzinga coverage of HC Wainwright PT raise
• Neutral Sentiment: Earnings‑call commentary highlighted record revenue and strategic growth plans (clinical and commercial expansion) but also discussed operational challenges and execution risks that management must resolve to sustain margin improvement — mixed signal for investors. NovoCure Q4 2025 Earnings Call Transcript Earnings call highlights
• Negative Sentiment: Despite the operational positives, NovoCure remains unprofitable (negative net margin and ROE) and analysts still model negative full‑year EPS; execution risk on margins and path to profitability keeps valuation under pressure. Zacks summary of Q4 results and financial metrics

NovoCure Company Profile

NovoCure is a global oncology company pioneering Tumor Treating Fields (TTFields), a novel anti-mitotic therapy for solid tumors. The company’s non-invasive treatment platforms deliver low-intensity, alternating electric fields designed to disrupt cancer cell division. NovoCure’s approach offers an alternative modality to complement existing therapies in oncology, with a focus on hard-to-treat malignancies.

Founded in 2000 and headquartered in Haifa, Israel, NovoCure maintains a second operational center in Portsmouth, New Hampshire.